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The objective of the research was to formulate and evaluate selegiline hydrochloride loaded chitosan 
nanoparticles for the Parkinson’s therapy in order to improve its therapeutic effect and reducing dosing 
frequency. Taguchi method of design of experiments (L9 orthogonal array) was used to get optimized 
formulation. The selegiline hydrochloride loaded chitosan nanoparticles (SHPs) were prepared by ionic 
gelation of chitosan with tripolyphosphate anions (TPP) and tween 80 as surfactant. The SHPs had a 
mean size of (303.39 ± 2.01) nm, a zeta potential of +32.50mV, and entrapment efficiency of SHPs was 
86.200 ± 1.38%. The in vitro drug release of SHPs was evaluated in phosphate buffer saline (pH 5.5) 
using goat nasal mucosa and found to be 82.529% ± 1.308 up to 28 h. Release kinetics studies showed 
that the release of drug from nanoparticles was anomalous (non-fickian) diffusion indicating the drug 
release is controlled by more than one process i.e. superposition of both phenomenon, the diffusion 
controlled as well as swelling controlled release. SHPs showed good stability results as found during 
stability studies at different temperatures as mentioned in ICH guidelines. The results revealed that 
selegiline hydrochloride loaded chitosan nanoparticles are most suitable mode of delivery of drug for 
promising therapeutic action.
Uniterms: Chitosan/nanoparticles/evaluation. Chitosan/nanoparticles/formulation. Selegiline 
hydrochloride/nanoparticles/drug release. Parkinson’s therapy. Polymeric nanoparticles/formulation. 
Polymeric nanoparticles/evaluation. Taguchi Design.
O objetivo da pesquisa foi formular e avaliar nanopartículas de quitosana contendo cloridrato de 
selegilina para terapia do Parkinson, a fim de melhorar o seu efeito terapêutico e reduzir a frequência 
de dosagem. Método de Taguchi, de planejamento experimental, (L9 matriz ortogonal) foi usado 
para obter a formulação otimizada. As nanopartículas de quitosana contendo cloridrato de selegilina 
(PCHs) foram preparadas por gelificação iônica de quitosana com ânions tripolifosfato (TPP) e Tween 
80 como tensoativo. As PCHs apresentaram tamanho médio de (303.39 ± 2,01) nm, potencial zeta de 
+32.50 mV e eficiência de encapsulação de 86.200±1,38%. A liberação do fármaco in vitro foi avaliada 
em solução salina de tampão fosfato (pH 5,5), usando a mucosa nasal de cabra e o resultado encontrado 
foi de 82.529% ± 1.308, acima de 28 h. Estudos de cinética de liberação mostraram que a liberação 
do fármaco das nanopartículas foi por difusão anômala (não fickiana), indicando que é controlada por 
mais de um processo, ou seja, a superposição dos fenômenos de difusão controlada e intumescimento. 
As PCHs mostraram resultados de boa estabilidade, encontrada durante os estudos de estabilidade em 
temperaturas diferentes, como mencionado em diretrizes do ICH. Os resultados revelaram que o sistema 
de nanopartículas de quitosana contendo cloridrato de selegilina é o mais adequado sistema de liberação 
de fármacos de ação terapêutica promissora.
Unitermos: Quitosana/nanopartículas/avaliação. Cloridrato de selegilina/nanopartículas/sistema 
de liberação. Doença de Parkinson/terapia. Nanopartículas poliméricas/formulação. Nanopartículas 
poliméricas/avaliação. Planejamento de Taguchi.
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INTRODUCTION
Parkinson’s disease, also known as Paralysis 
Agitans, is an idiopathic neurodegenerative disorder of 
central nervous system. It is a consequence of death of 
dopamine containing cells in substantia nigra, a region 
in midbrain (Jankovisc, 2008) Monoamine oxidase 
(MAO), an intracellular enzyme, degrades dopamine 
which diminishes the net amount of dopamine available. 
To prevent the degradation of dopamine, MAO inhibitors 
are prescribed. Selegiline hydrochloride is best known 
as an irreversible inhibitor of MAO. It is a levorotatory 
acetylenic derivative of phenethylamine (Davie, 2008). 
It inhibits MAO by acting as a ‘suicide’ substrate for 
the enzyme. It is converted by MAO to an active moiety 
which combines irreversibly with the active site and/or 
the enzyme’s essential FAD cofactor. Because selegiline 
has greater affinity for type B rather than for type A active 
sites, it can serve as a selective inhibitor of MAO type B 
if it is administered at the recommended doses (Pae et al., 
2007). Selegiline hydrochloride has high protein binding 
(up to 99%), thus one best approach to overcome this 
problem is to give intranasally which target drug directly 
to brain via absorption through olfactory mucosa (Sharma, 
Khatri, Patil, 2010). For this purpose, nanoparticles made 
up of mucoadhesive and biocompatible polymers serve 
the best. Chitosan nanoparticles are submicron colloidal 
drug carrier systems which are biodegradable, non-toxic 
and non-immunogenic (Wilson et al., 2008). Chitosan 
nanoparticles have various advantages like: site specific 
targeting, prevention of dose dumping via its sustained 
and controlled release nature and its mucoadhesive nature 
(Kockisch et al. 2003). These attributes indirectly help 
in reducing dose and frequency of administration which 
improves patient compliance (Sailaja, Amareshwar, 
Chakravarty, 2010).
In the present work, we attempted to develop 
sustained release mucoadhesive selegilline hydrochloride 
loaded chitosan nanoparticles which can serve as 
intranasal drug delivery systems. The formulation was 
characterized using scanning electron microscopy (SEM), 
zeta potential, polydispersity index and entrapment 
efficiency. Permeation of drug from formulation through 
excised goat nasal mucosa was examined by an in vitro 
method.
MATERIAL AND METHODS
Material
Selegiline hydrochloride was received as gift sample 
from Neha Pharma Pvt. Ltd., Mumbai, India. Chitosan 
(85% deacetylated) was purchased from Sigma Aldrich 
Pvt. Ltd., Mumbai, India. Sodium Tripolyphosphate and 
Tween 80 were purchased from Loba Chemie Pvt. Ltd. 
(Mumbai, India) and S.D Fine-Chem Pvt. Ltd. (Mumbai, 
India), respectively. All other reagents were of analytical 
grade and used as purchased.
Statistical experimental design for formulation 
optimization
The Taguchi method of design of experiments is a 
statistical tool, which mainly relies upon the systematic 
approach of conducting minimum number of experiments 
with the use of a mathematical instrument known as 
orthogonal arrays (OA) (Varshosaz et al., 2008). The 
method is primarily utilized to envisage the contribution 
of each variables and their level to attain optimum 
combination. The method also gives full description of 
all the factors that affect the performance parameters. 
Based on the number of factors and their levels, L9 
(34) orthogonal array was employed (Senthilkumar, 
Vaidyanathan, Sivaraman, 2010). It includes four factors 
(formulation variables) i.e. polymer concentration (%w/v), 
cross-linking agent concentration (%w/v), surfactant 
concentration (%v/v) and stirring speed (rpm) were 
selected. All the factors were assigned three levels i.e. 
low, medium and high as shown in Table I. L9 orthogonal 
array is explained in Table II, which describes number 
of formulations to be developed for optimization. Apart 
from designing a formulation table, optimizations are done 
on the basis of two main approaches and signal to noise 
ratio (S/N ratio). S/N ratio takes into account the mean 
and variation between results (Dobrazanski, Domagala, 
Silva, 2007). The two approaches are smaller-the-better 
and larger-the-better. Smaller-the-better is usually the 
chosen S/N ratio for all undesirable characteristics like 
“defects”, for which the ideal value is zero. Examples are 
size of nanoparticles, polydispersity index while larger-
the-better is taken when ideal value is larger. Examples 
are drug entrapment efficiency, and drug loading, among 
others (Jahanshahi, Najafpour, Rahimnejad, 2008).
Preparation of selegiline hydrochloride loaded 
chitosan nanoparticles
Chitosan nanoparticles containing the drug 
selegiline hydrochloride were prepared by ionotropic 
gelation technique (Calvo et al., 1997). Accurately 
weighed chitosan was dissolved in 1% v/v acetic acid 
solution, to which tween 80 and drug was added. Sodium 
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TABLE I - Experimental control factors and their levels for chitosan nanoparticles formulation
S.No. Variables 
Levels 
Low (1) Medium (2) High(3) 
1. Polymer Concentration 1:0.1% 1:0.2% 1:1.5% 
2. Concentration of Tween 80 0.25 % 0.50 % 0.75 % 
3. Concentration of TPP 0.1% 0.25% 0.5% 
4. Stirring speed (rpm) 1000 1500 2000
TABLE II - Taguchi L9 (34) orthogonal array for chitosan 
nanoparticles formulation
Batches
Parameters
A B C D
SHP1 1 1 1 1
SHP2 1 2 2 2
SHP3 1 3 3 3
SHP4 2 1 2 3
SHP5 2 2 3 1
SHP6 2 3 1 2
SHP7 3 1 3 2
SHP8 3 2 1 3
SHP9 3 3 2 1
FIGURE 1 - Representative Chromatogram of selegiline 
hydrochloride (Peak at 7.762 min).
tripolyphosphate (TPP) was dissolved in distilled water. 
To the chitosan-drug solution, TPP solution was added 
dropwise through a no.4 syringe needle and continuously 
stirred using mechanical stirrer (Remi Motors-RO-123, 
RPM 4000) at room temperature for 30 min, which leads 
to the formation of nanoparticles. Subsequently pH was 
adjusted to 5.5 with the help of certain amount of 1 N 
HCl or NaOH and then centrifuged at 12000 rpm, using 
refrigerated centrifuge (SIGMA 3-18K, Sartorius) (Wang, 
Chi, Tang, 2008).
HPLC analytical method
The HPLC system for selegiline hydrochloride 
included a VP Shimadzu Liquid Chromatograph LC-10AT 
pump and a SPD-10A ultraviolet (UV)/visible detector. A 
25-cm-long, 4-mm inner diameter stainless-steel RP-18 
column (Merck, Darmstadt, Germany) was used. The 
mobile phase was acetonitrile: pH 7.0 buffer (65:35) at 
a flow rate of 1.0 mL/min. The UV/visible detector was 
set to 205 nm (Chena et al., 2011). The retention time 
of selegiline hydrochloride was 7.75 min (Chena et al., 
2011). The representative HPLC chromatogram is shown 
in Figure 1.
Characterization of Chitosan nanoparticles
Shape and surface morphology
Shape and surface morphology of chitosan 
nanoparticles was visualized by scanning electron 
microscopy (LEO-430 Cambridge and U.K). Samples 
were prepared by lightly sprinkling nanoparticles on a 
double adhesive tape, on an aluminum stub. The stubs 
were then coated with gold to a thickness of 200 to 500 A0 
under an argon atmosphere using gold sputter module 
in a high vacuum evaporator. The samples were then 
randomly scanned and photomicrographs taken at different 
magnifications with SEM (Paharia et al., 2007).
Particle size and zeta potential measurement
Particle size was measured with the help of photon 
correlation microscopy. For the determination of particle 
size, samples were prepared by tenfold dilution of 1ml 
of nanoparticulate suspension with distilled water. The 
analysis was carried out in triplicate. Average particle 
size and polydispersity index were measured by photon 
correlation spectroscopy at 90o angle at 25 oC. Zeta potential 
was determined by the electrophoretic mobility of chitosan 
nanoparticles in U type tube at 25 ºC, using a Zetasizer 
(3000HS Malvern Instruments, UK) (Alhaj et al., 2008).
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Drug entrapment efficiency
The entrapment efficiency of the formulation was 
determined upon the centrifugation of fixed quantity 
of aqueous nanoparticulate suspension (about 10 mL) 
at 12000 rpm for 30 minutes at 20 oC (SIGMA 3-18K, 
Sartorious). The absorbance of unencapsulated drug was 
evaluated in the supernatant via HPLC system using 
calibration curve with plain chitosan nanoparticles (SHPs) 
as blank which had also been prepared and treated similar 
to the drug loaded nanoparticles (Joseph, Sharma, 2007). 
The analysis was carried out in triplicate and mean taken. 
The drug entrapment of chitosan nanoparticles was 
calculated by the following equation.
% Drug Entrapment
Efficiency × 100=
Amount of drug
in supernatant
Initial amount
of drug added
In vitro permeation studies 
In vitro permeation study was conducted using 
Keshary-Chien (K-C) cell with an effective diffusion area 
of 2.0 cm2 and a cell volume of 25 mL. The diffusion cells 
were thermoregulated with a water jacket at 37±2 ºC. 
Excised goat nasal mucosa was used for the evaluation of 
formulation permeation which was obtained from local 
slaughter house within 15 minutes of goat sacrifice. After 
skin removal, the nose was stored on ice cold phosphate 
buffer (pH 5.5) and nasal mucosa was carefully removed 
using forceps and surgical scissors. The mucosal tissues 
were immediately immersed in Ringer’s solution. The 
freshly excised nasal mucosa was mounted on the diffusion 
cell and 10 mL of aqueous drug loaded nanoparticulate 
suspension (containing drug equivalent to 10 mg) was kept 
on it. The receptor chamber was filled with fresh saline 
(phosphate buffer pH 5.5). 1ml of sample aliquots were 
withdrawn at predetermined time intervals and subsequently 
replenished with an equal amount of phosphate buffer. The 
samples were filtered and diluted appropriately. The samples 
were analyzed using HPLC system (Basu, Chakrabatorty, 
Bandyopadhyay, 2009; Basu, Bandyopadhyay, 2010).
Release kinetics studies
The release kinetics of drug was studied by plotting 
the results of the in vitro drug release study with various 
kinetic models like zero order (cumulative percent drug 
release vs time), first order (log cumulative percent drug 
release vs time), Higuchi’s kinetics (cumulative percent 
drug release vs √time), and Korsmeyer and Peppas 
equation (log cumulative percentage of drug release vs 
log time) (Bourne et al., 2002; Korsmeyer et al., 1983).
Stability studies
A study was also carried out to assess the stability 
of Selegiline hydrochloride loaded chitosan nanoparticles 
(SHP4). For this purpose, samples were kept in borosilicate 
glass vials and stored at room temperature, refrigerator 
(5±1 ºC) and 45±1 ºC (75% relative humidity) in the 
stability chamber. Samples were analyzed at the intervals 
of 0, 7, 14, 21, 28, 35 and 45 days for their drug content 
as well as any changes in physical appearance (Zhang et 
al., 1996).
RESULTS AND DISCUSSION
Chitosan nanoparticles can be prepared by several 
techniques reported in literature like microemulsion method, 
ionotropic gelation method and solvent emulsification 
diffusion method. Ionotropic gelation method being mild 
with simple laboratory set-up was used in the present study. 
Remarkably high percent drug entrapment (86.200 ± 1.38%) 
and small particle size (303.39±2.01 nm) was observed with 
this method. In this method, polymer (chitosan), cross-
linking agent (sodium tripolyphosphate) and surfactant 
(tween 80) were selected. pH of the formulation was 
considered as important factor as it determines the degree 
of cross-linking and also the pH of delivery site. Cross-
linking of polymer is higher at acidic pH as reported. They 
concluded that at pH 3, only phosphoric ions are present 
which cause ionic cross-linking while at pH 9, cross-linking 
via deprotonation is achieved (Bhumkar, Pokharkar, 2009).
Taguchi design enabled selection of optimized 
formulation. Four factors (viz. drug to polymer ratio, 
concentration of surfactant, concentration of cross-linking 
agent and stirring speed) were selected, as these are most 
important factors (independent variables), which can 
affect particle size, entrapment efficiency and in vitro 
drug release (dependent variables). The range for drug 
to polymer ratio was taken from 1:0.1 to 1:1.5 w/w. In 
comparison with other concentrations, 1:0.1 w/w showed 
highest entrapment (41.46% ± 0.65) with minimum 
particle size (415 nm ± 0.23). Different concentrations of 
cross-linking agent were also taken from 0.10 to 0.5%, 
out of which 0.25% was found as optimum on the basis of 
smallest particle size (506 nm ± 0.76) and high entrapment 
(56.23% ± 0.43). Concentration of surfactant i.e. 0.5%v/v 
tween 80 was selected on the basis of smallest particle size 
(415 nm ± 0.23) as well as the fact that no aggregation was 
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observed up to 24 hours. Stirring speed of 1500 rpm was 
selected as optimum with respect to particle size (415 nm 
± 0.45) and entrapment efficiency (52.84%±0.38).
On the basis of evaluation parameters, optimized 
formulation should have medium level of drug to polymer 
ratio (1:0.2% w/v), low level of surfactant (0.25% v/v), 
medium level of cross-linking agent (0.25% w/v) and high 
level of stirring speed (3000 rpm), as per the three levels 
of factors taken for experimental design.
The particle size and zeta potential of chitosan 
nanoparticles was analyzed by PCS and zetasizer. 
Nanoparticles were round in shape with a smooth 
appearance as shown in Figure 2. The values for the 
average particle size, zeta potential and polydispersity 
index are tabulated in Table III. Optimized formulation 
showed an average particle size and polydispersity index 
of 303.39±2.01 and 0.313±0.28, respectively. The zeta 
potential was found to be +28.5 mV.
On the basis of Taguchi design, smaller-the-better 
of S/N ratio was considered for the particle size and 
polydispersity index. SHP4 showed minimum average 
particle size and polydispersity index of 303.39 ± 2.01 and 
0.313 ± 0.28, respectively, which can be taken into account 
as optimized in terms of particle size and polydispersity 
index. Shape and surface morphology of the selegiline 
hydrochloride loaded chitosan nanoparticles were 
visualized by scanning electron microscopy (SEM). They 
were found to be spherical and with a smooth appearance 
as shown in Figure 2. Chitosan nanoparticles displayed 
uniform size distribution. This may be attributed to the 
optimum combination of drug to polymer ratio and stirring 
speed. Polymer concentration (0.2%-medium level) was 
not so viscous, thus high stirring speed (3000 rpm) could 
easily breakdown the formed nanoparticles. As reported 
in literature, higher concentration of polymer, results in 
viscous solution which may resists the particle breakdown 
by stirring and lead to increase in particle size (Thagele, 
Mishra, Pathak, 2011). Smaller size helps in targeting 
and increased penetration of drug through biological 
membranes (Vasir, Reddy, Labhasetwar, 2005).
The measurement of the zeta potential allows 
predictions of storage stability of colloidal dispersion. 
In general, particle aggregation is less likely to occur 
for charged particles (high zeta potential) due to electric 
repulsion (Hans, Lowman, 2002). The mean zeta 
potential was found to be +32.50±1.93 mV, which may 
be attributed to the positive charges on polymer matrices 
and surfactant’s mixture. Tween 80 also provides steric 
stability to nanoparticles (Lim, Kim, 2002).
TABLE III - Data for evaluation parameters of selegiline hydrochloride loaded nanoparticles
Formulations Average particle size ± S.D Zeta Potential ± S.D
Polydispersity 
Index ± S.D
Entrapment 
Efficiency ± S.D
SHP1 546.54 ± 1.85 33.50 ± 0.83 0.519 ± 1.93 85.950 ± 1.20
SHP2 517.53 ± 0.83 21.71 ± 0.28 0.554 ± 2.34 84.070 ± 2.40
SHP3 437.28 ± 1.02 22.98 ± 0.64 0.472 ± 1.30 78.500 ±1.92
SHP4 303.39 ± 2.01 32.50 ± 1.93 0.313 ± 0.28 86.200 ± 1.38
SHP5 349.48 ± 0.74 26.50 ± 2.91 0.314 ± 0.74 84.660 ± 0.28
SHP6 624.86 ± 1.73 27.10 ± 0.74 0.593 ± 1.08 83.349 ± 1.93
SHP7 658.48 ± 1.20 26.80 ± 0.76 0.602 ± 1.29 83.801 ± 1.06
SHP8 574.89 ± 0.29 35.40 ± 1.83 0.652 ± 1.38 81.000 ± 0.48
SHP9 536.78 ± 1.32 36.83 ± 1.94 0.507 ± 2.18 82.670 ± 0.93
(Values are mean ± standard deviation)
FIGURE 2 - SEM Photomicrograph of selegiline hydrochloride 
loaded Chitosan nanoparticles.
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Entrapment efficiency of selegiline hydrochloride 
loaded chitosan nanoparticles was analyzed and data is 
shown in Table III. According to Taguchi design, larger-
the-better of S/N ratio is considered as optimum. SHP4 
showed average drug entrapment efficiency of 86.200% 
± 1.38, which is higher amongst other formulations. 
Percent drug entrapment was found to be high i.e. 
86.200 ± 1.38 in formulation SHP4, as compared to 
other formulations. Effective entrapment is totally 
based on nature of polymer and solubility of drug in it. 
Since chitosan is a hydrophilic polymer and selegiline 
hydrochloride is also freely soluble in water. Thus, more 
drugs could be entrapped into the polymer matrices. 
Apart from the nature of drug and polymer, concentration 
of polymer (medium level) was enough to entrap more 
amount of drug, which leads to increase in entrapment 
(Thagele, Mishra, Pathak, 2011). If the concentration of 
polymer is further increased, a decrease in entrapment 
is observed, which may be due to higher viscosity of the 
polymeric solution which hinders diffusion of drug in the 
polymer. Inspite of optimum concentration of chitosan, 
concentration of cross-linking agent played a major 
role in high entrapment. Higher concentration of cross-
linking agent could gelate more amount of polymer, 
thereby increasing the amount of drug entrapped into the 
nanoparticles (Deng, Zhou, Luo, 2006).
In vitro drug release was carried out using K-C 
(diffusion) cell. Figure 3 showed release profile of 
selegiline hydrochloride from chitosan nanoparticles. 
The release of drug from the drug-loaded formulations 
varied from 58.182 ± 1.135 to 82.529 ± 1.308 for 28 
hours, depending on the drug-to-polymer ratio. The in 
vitro release profile of drug loaded chitosan nanoparticles 
revealed that the optimized batch showed an initial 
burst release up to 4.384% ± 1.92, which may be due 
to presence of adsorbed drug on the surface of polymer, 
which was followed by sustained release of 76.74 ± 1.308 
up to 28 hours because the drug slowly get diffused to the 
surface through the polymer core. This release pattern 
may contribute in presenting the drug immediately after 
instilling in the nasal cavity and sustained release up to 
24 hours would contribute to lower dosing frequency. 
The slow release of the selegiline hydrochloride from all 
formulations suggests homogeneous entrapment of the 
drug throughout the systems.
It was found that the in vitro drug release of SHP4 
was best explained by zero order, as the plots showed 
the highest linearity (R2 = 0.979), followed by Higuchi’s 
equation (R2 = 0.889) and first order (R2 = 0.787). The 
corresponding plot (log % cumulative drug release vs 
log time) for the Korsmeyer-Peppas equation indicated 
good linearity (R2 = 0.969). The release exponent ‘n’ was 
found to be 1.002. On fitting the in vitro release data into 
different equations, optimized formulation showed zero 
order release as it has high linearity, followed by Higuchi’s 
equation and first order as shown in Table IV. The value 
of release component ‘n’ obtained via Korsmeyer-Peppas 
equation is 0.969 which appears to indicate the anomalous 
(non-fickian) diffusion indicating that the drug release is 
controlled by more than one process i.e. superposition of 
both phenomenon, the diffusion controlled and swelling 
controlled release (Deng, Zhou, Luo, 2006).
The results of drug content of optimized formulation 
SHP4 after 45 days of stability testing at different storage 
conditions were shown in Table V. The results of stability 
studies clearly demonstrate that the formulation is more 
stable when stored at 4 ºC and room temperature than at 
45 ± 2 ºC/75% RH. This may be due to nanoparticulate 
degradation at higher RH and temperature (Nesalin, Smith, 
2012).
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FIGURE 3 - In vitro drug release profiles of selegiline hydrochloride loaded chitosan nanoparticles.
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TABLE IV - Release parameters of chitosan nanoparticles (SHP4)
Formulation Zero order First order Higuchi Korsmeyer-peppas
SHP4
K R2 K R2 K R2 N R2
3.129 0.979 0.061 0.787 16.82 0.889 1.002 0.969
TABLE V - Stability studies of optimized formulation SHP4
S. No. Sampling Interval (days)
Drug Content (%)
5 ± 1 oC Room temperature 45 ± 2 oC/75% RH
1. 0th 100 100 100
2. 7th 99.53 ± 0.21 99.47 ± 0.22 92.56 ± 0.45
3. 14th 99.28 ± 0.07 98.83 ± 0.13 85.93 ± 0.36
4. 21th 99.93 ± 0.84 98.27 ± 0.08 76.83 ± 0.39
5. 28th 99.75 ± 0.12 97.88 ± 0.17 70.97 ± 0.29
6. 35th 98.43 ± 0.12 97.03 ± 0.12 63.86 ± 0.13
7. 45th 98.18 ± 0.03 96.58 ± 0.34 57.03 ± 0.84
(Values are mean ± standard deviation)
CONCLUSION
Selegil ine Hydrochloride loaded chitosan 
nanoparticles were successfully formulated via ionotropic 
gelation technique using Taguchi design for optimization. 
The obtained nanoparticles would easily penetrate nasal 
mucosa by virtue of particle size. Formulation displayed 
sustained release up to 24 hours that may help to cut down 
multiple dosing to once-a-day. Therefore, it could be a 
potential drug delivery system for the targeted therapy 
of disease.
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